Paradigm Biopharmaceuticals Limited (ASX:PAR)
Australia · Delayed Price · Currency is AUD 0.2450
0.00 (0.00%)
Sep 18, 2026, 4:10 PM AEST
ASX:PAR Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | - | - | - | - | 0.08 |
| - | - | - | - | 0.08 | |
Revenue Growth | - | - | - | - | 285.52% |
Cost of Revenue | 0.01 | 0.02 | 0.01 | 0.02 | 0.14 |
Gross Profit | -0.01 | -0.02 | -0.01 | -0.02 | -0.06 |
Selling, General & Admin | 7.26 | 5.58 | 6.77 | 7.39 | 8.85 |
Research & Development | 53.92 | 17.74 | 58.33 | 52.68 | 39.01 |
Operating Expenses | 61.18 | 23.32 | 65.1 | 60.07 | 47.87 |
Operating Income | -61.19 | -23.34 | -65.11 | -60.09 | -47.93 |
Interest Expense | -2.46 | -0.01 | -0.01 | -0.02 | -0.03 |
Interest & Investment Income | 0.42 | 0.36 | 0.41 | 1.4 | 0.05 |
Currency Exchange Gain (Loss) | -0.92 | 0.01 | -0.05 | -0.39 | 0.89 |
Other Non Operating Income (Expenses) | 7.83 | 6.75 | 6.04 | 7.09 | 7.76 |
EBT Excluding Unusual Items | -56.33 | -16.24 | -58.73 | -52 | -39.25 |
Gain (Loss) on Sale of Assets | -0.01 | - | - | - | - |
Asset Writedown | - | -2.53 | - | - | - |
Other Unusual Items | - | - | - | 0.09 | - |
Pretax Income | -56.33 | -18.77 | -58.73 | -51.91 | -39.25 |
Net Income | -56.33 | -18.77 | -58.73 | -51.91 | -39.25 |
Net Income to Common | -56.33 | -18.77 | -58.73 | -51.91 | -39.25 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 370 | 315 | 293 | 250 | 233 |
Shares Outstanding (Diluted) | 370 | 315 | 293 | 250 | 233 |
Shares Change | 17.66% | 7.23% | 17.43% | 7.34% | 1.21% |
EPS (Basic) | -0.15 | -0.06 | -0.20 | -0.21 | -0.17 |
EPS (Diluted) | -0.15 | -0.06 | -0.20 | -0.21 | -0.17 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -43.69 | -15.99 | -65.94 | -45.19 | -32.21 |
Free Cash Flow Per Share | -0.12 | -0.05 | -0.23 | -0.18 | -0.14 |
Gross Margin | - | - | - | - | -81.45% |
Operating Margin | - | - | - | - | -60498.78% |
Profit Margin | - | - | - | - | -49542.54% |
Free Cash Flow Margin | - | - | - | - | -40650.90% |
EBITDA | -61.04 | -23.19 | -64.97 | -59.93 | -47.74 |
D&A For EBITDA | 0.15 | 0.15 | 0.15 | 0.15 | 0.19 |
EBIT | -61.19 | -23.34 | -65.11 | -60.09 | -47.93 |